Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8
The experimentally established mechanism targets of Gabapentin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 1/20 | 0.92 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.92 |
| ▸ | USP2 | O75604 | 1/20 | 0.92 |
| ▸ | LMNA | P02545 | 1/20 | 0.92 |
| ▸ | TSHR | P16473 | 1/20 | 0.92 |
| ▸ | BLM | P54132 | 1/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.92 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gabapentin SCHEMBL3238880 | 1.00 | CYP1A2 (0.92) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL2853833 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Hydrochloric Acid SCHEMBL7340062 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL6672099 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL6689206 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL26730 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL7047893 | 0.96 | CYP1A2 (0.92) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL28968673 | 0.96 | CYP1A2 (0.92) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL6544499 | 0.96 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL8343 | 0.96 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010023694-A2 | CRYSTALLINE FORMS OF GABAPENTIN AND PROCESS THEREOF | HIKAL LTD (IN) | 2010-03-04 | — | — | WO | claimed |
| EP-0340677-B1 | Gabapentin monohydrate and a process for producing the same | WARNER LAMBERT CO (US) | 1994-02-02 | — | — | EP | claimed |
| US-4960931-A | Anticonvulsants | WARNER-LAMBERT COMPANY (US) | 1990-10-02 | — | — | US | claimed |
| EP-0340677-A2 | Gabapentin monohydrate and a process for producing the same | WARNER-LAMBERT COMPANY (US) | 1989-11-08 | — | — | EP | claimed |
| US-11931334-B2 | Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal | PLEOPHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-115605195-A | Methods and compositions for treating cannabis use disorders and alleviating cannabinoid withdrawal | 普利欧制药有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| EP-4114379-A1 | METHODS AND COMPOSITIONS FOR TREATING CANNABIS USE DISORDER AND MITIGATING CANNABINOID WITHDRAWAL | Pleopharma, L.L.C. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11197846-B2 | Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal | PLEOPHARMA L.L.C. (US) | 2021-12-14 | — | — | US | disclosed |
| WO-2021178700-A1 | METHODS AND COMPOSITIONS FOR TREATING CANNABIS USE DISORDER AND MITIGATING CANNABINOID WITHDRAWAL | Pleopharma, L.L.C. (US) | 2021-09-10 | — | — | WO | disclosed |
| US-20210275492-A1 | METHODS AND COMPOSITIONS FOR TREATING CANNABIS USE DISORDER AND MITIGATING CANNABINOID WITHDRAWAL | PLEOPHARMA, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20100280118-A1 | Methods for treating substance dependence | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2010023694-A2 | CRYSTALLINE FORMS OF GABAPENTIN AND PROCESS THEREOF | HIKAL LTD (IN) | 2010-03-04 | — | — | WO | disclosed |
| US-6372792-B1 | Method for treating anxiety, anxiety disorders and insomnia | CHOUINARD GUY (CA) | 2002-04-16 | — | — | US | disclosed |
| US-6054482-A | Lactam-free amino acids | GODECKE AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |
| EP-0340677-B1 | Gabapentin monohydrate and a process for producing the same | WARNER LAMBERT CO (US) | 1994-02-02 | — | — | EP | disclosed |
| US-5091567-A | Reacting cyclohexanone with phosphonoacetic acid ester, condensing with nitromethane, reducing, hydrolyzing | GODECKE AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | disclosed |
| US-5068413-A | Process for the preparation of cyclic amino acids and intermediates useful in the process | GODECKE AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | disclosed |
| US-4960931-A | Anticonvulsants | WARNER-LAMBERT COMPANY (US) | 1990-10-02 | — | — | US | disclosed |
| US-4894476-A | ANTISCALING AGENTS | WARNER-LAMBERT COMPANY (US) | 1990-01-16 | — | — | US | disclosed |
| EP-0340677-A2 | Gabapentin monohydrate and a process for producing the same | WARNER-LAMBERT COMPANY (US) | 1989-11-08 | — | — | EP | disclosed |